Trials / Recruiting
RecruitingNCT06564272
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KC1036 | For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle. |
Timeline
- Start date
- 2024-09-27
- Primary completion
- 2027-04-01
- Completion
- 2028-04-01
- First posted
- 2024-08-21
- Last updated
- 2024-08-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06564272. Inclusion in this directory is not an endorsement.